Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease

AUTHOR

OTS

DATE

December 31, 2018

CATEGORIES

Antisense/RNase H

SHARE

Post Views: 346

Cansby E, Nuñez-Durán E, Magnusson E, Amrutkar M, Booten SL, Kulkarni NM, Svensson LT, Borén J, Marschall HU, Aghajan M, Mahlapuu M.
Cell Mol Gastroenterol Hepatol. 2018 Dec 19.

PubMed

Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease

Related articles

Systematic screening identifies therapeutic antisense oligonucleotides for Hutchinson-Gilford progeria syndrome

α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease

Antisense oligonucleotide therapy in a humanized mouse model of MECP2 duplication syndrome

Binding of phosphorothioate oligonucleotides with RNase H1 can cause conformational changes in the protein and alter the interactions of RNase H1 with other proteins

Variant-selective stereopure oligonucleotides protect against pathologies associated with C9orf72-repeat expansion in preclinical models

Short antisense oligonucleotides alleviate the pleiotropic toxicity of RNA harboring expanded CGG repeats

Login to your account

Reset Password

Signup to your Account

Answers

Job Alerts

Account Activation